Dexcom (NASDAQ:DXCM), a leader in continuous glucose monitoring (CGM), announced today that the company has received CE Mark for its Dexcom G6 System for people with diabetes ages two years and up. As quoted in the press release: “The Dexcom G6 represents the future of diabetes management. Not only does the product eliminate the need for …

Dexcom (NASDAQ:DXCM), a leader in continuous glucose monitoring (CGM), announced today that the company has received CE Mark for its Dexcom G6 System for people with diabetes ages two years and up.

As quoted in the press release:

“The Dexcom G6 represents the future of diabetes management. Not only does the product eliminate the need for fingersticks, but it also maintains the performance, connectivity and accuracy that the diabetes community has come to expect from Dexcom CGM,” said John Lister, Dexcom’s General Manager for EMEA.
The groundbreaking Dexcom G6 will be available in the U.K. and Ireland this month and is expected to be introduced into other European countries later this year. Dexcom G6 encompasses new features that empower users to take control of their diabetes:

Click here to read the full press release.

ce mark dexcom dexcom g6 system diabetes nasdaq:dxcm Medical Device Investing